Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study

LMs are associated with poor prognosis in pMMR mCRC and do not predict resistance to the addition of atezolizumab to FOLFOXIRI/bevacizumab. Immunoscore-IC seems to retain its predictive impact also among patients with LMs.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-02-01
DOI
https://doi.org/10.1016/j.esmoop.2025.104135
Citations
6
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
5.23

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study

Veronica Conca, Clara Ugolini, Maria Alessandra Calegari, Emiliano Tamburini et al.
6 citations
ESMO Open
Colorectal Cancer Treatments and Studies
5.23
article

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study

Veronica Conca, Clara Ugolini, Maria Alessandra Calegari, Emiliano Tamburini, Lisa Salvatore, C. Antoniotti, G. Aprile, Caterina Sciortino, S. Tamberi, Sara Lonardi, F. Bergamo, P. Ciracì, Jérôme Galon, Martina Carullo, Daniele Rossini, Giuliana Ritorto, Carla Boccaccio, Chiara Cremolini, F. Pietrantonio, Alessandro Passardi
article en
6 citations

Abstract

LMs are associated with poor prognosis in pMMR mCRC and do not predict resistance to the addition of atezolizumab to FOLFOXIRI/bevacizumab. Immunoscore-IC seems to retain its predictive impact also among patients with LMs.

ESMO OpenVol. 10(2)
Università Cattolica del Sacro Cuore (IT), University of Pisa (IT), Inserm (FR), Université Paris Cité (FR), Agostino Gemelli University Polyclinic (IT), Sorbonne Université (FR), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Centre de Recherche des Cordeliers (FR), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Ospedale di Cattinara (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Laboratoire d’immunologie intégrative du cancer (FR), Ospedale San Bortolo (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT)
Università di Pisa
Good health and well-being
Openalex Percentile: Top 5%
Colorectal Cancer Treatments and Studies
5.23
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.